|
1
|
Coleman RL, Monk BJ, Sood AK and Herzog
TJ: Latest research and treatment of advanced-stage epithelial
ovarian cancer. Nat Rev Clin Oncol. 10:211–24. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sato S and Itamochi H: Neoadjuvant
chemotherapy in advanced ovarian cancer: Latest results and place
in therapy. Ther Adv Med Oncol. 6:293–304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Randle RW, Swett KR, Swords DS, Shen P,
Stewart JH, Levine EA and Votanopoulos KI: Efficacy of
cytoreductive surgery with hyperthermic intraperitoneal
chemotherapy in the management of malignant ascites. Ann Surg
Oncol. 21:1474–1479. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ba M, Long H, Zhang X, Tang Y, Wu Y, Yu F,
Wang S and Cui S: Different sequential approaches of cytoreductive
surgery and hyperthermic intraperitoneal chemotherapy in treating
ovarian cancer with malignant ascites. J Cancer Res Clin Oncol.
140:1497–1506. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ba MC, Cui SZ, Lin SQ, Tang YQ, Wu YB,
Wang B and Zhang XL: Chemotherapy with laparoscope-assisted
continuous circulatory hyperthermic intraperitoneal perfusion for
malignant ascites. World J Gastroenterol. 16:1901–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ba MC, Long H, Cui SZ, Tang YQ, Wu YB,
Zhang XL, Tang HS and Bai SX: Multivariate comparison of
B-ultrasound guided and laparoscopic continuous circulatory
hyperthermic intraperitoneal perfusion chemotherapy for malignant
ascites. Surg Endosc. 27:2735–2743. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cui S, Ba M, Tang Y, Liu J, Wu Y, Wang B,
Zhang X, Tang H and Zhong S: B ultrasound-guided hyperthermic
intraperitoneal perfusion chemotherapy for the treatment of
malignant ascites. Oncol Rep. 28:1325–1331. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Facchiano E, Scaringi S, Kianmanesh R,
Sabate JM, Castel B, Flamant Y, Coffin B and Msika S: Laparoscopic
hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment
of malignant ascites secondary to unresectable peritoneal
carcinomatosis from advanced gastric cancer. Eur J Surg Oncol.
34:154–158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garofalo A, Valle M, Garcia J and
Sugarbaker PH: Laparoscopic intraperitoneal hyperthermic
chemotherapy for palliation of debilitating malignant ascites. Eur
J Surg Oncol. 32:682–685. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Parson EN, Lentz S, Russell G, Shen P,
Levine EA and Stewart JH 4th: Outcomes after cytoreductive surgery
and hyperthermic intraperitoneal chemotherapy for peritoneal
surface dissemination from ovarian neoplasms. Am J Surg.
202:481–486. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Y, Endo Y, Fujita T, Ishibashi H,
Nishioka T, Canbay E, Li Y, Ogura S and Yonemura Y: Cytoreductive
surgery under aminolevulinic acid-mediated photodynamic diagnosis
plus hyperthermic intraperitoneal chemotherapy in patients with
peritoneal carcinomatosis from ovarian cancer and primary
peritoneal carcinoma: Results of a phase I trial. Ann Surg Oncol.
21:4256–4262. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chia CS, Tan WJ, Wong JF, Tan GH, Lim C,
Wang W, Sin EI, Tham CK, Soo KC and Teo MC: Quality of life in
patients with peritoneal surface malignancies after cytoreductive
surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg
Oncol. 40:909–916. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tan WJ, Wong JF, Chia CS, Tan GH, Soo KC
and Teo MC: Quality of life after cytoreductive surgery and
hyperthermic intraperitoneal chemotherapy: An Asian perspective.
Ann Surg Oncol. 20:4219–4223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Glehen O, Gilly FN, Arvieux C, Cotte E,
Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F and Elias
D; Association Française de Chirurgie, : Peritoneal carcinomatosis
from gastric cancer: A multi-institutional study of 159 patients
treated by cytoreductive surgery combined with perioperative
intraperitoneal chemotherapy. Ann Surg Oncol. 17:2370–2377. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tabrizian P, Shrager B, Jibara G, Yang MJ,
Romanoff A, Hiotis S, Sarpel U and Labow DM: Cytoreductive surgery
and hyperthermic intraperitoneal chemotherapy for peritoneal
carcinomatosis: Outcomes from a single tertiary institution. J
Gastrointest Surg. 18:1024–1031. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Graziosi L, Marino E and Donini A: Reply
to ‘Peritoneal carcinomatosis in patients with gastric cancer, and
the role for surgical resection, cytoreductive surgery, and
hyperthermic intraperitoneal chemotherapy’. Am J Surg. 208:158–159.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Scaringi S, Kianmanesh R, Sabate JM,
Facchiano E, Jouet P, Coffin B, Parmentier G, Hay JM, Flamant Y and
Msika S: Advanced gastric cancer with or without peritoneal
carcinomatosis treated with hyperthermic intraperitoneal
chemotherapy: A single western center experience. Eur J Surg Oncol.
34:1246–1252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zanon C, Bortolini M, Chiappino I, Simone
P, Bruno F, Gaglia P, Airoldi M, Deriu L and Mashiah A:
Cytoreductive surgery combined with intraperitoneal
chemohyperthermia for the treatment of advanced colon cancer. World
J Surg. 30:2025–2032. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Virzi S, Iusco D, Baratti D, Bonomi S,
Grassi A, Kusamura S and Deraco M: Pilot study of adjuvant
hyperthermic intraperitoneal chemotherapy in patients with
colorectal cancer at high risk for the development of peritoneal
metastases. Tumori. 99:589–595. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Deraco M, Baratti D, Inglese MG, Allaria
B, Andreola S, Gavazzi C and Kusamura S: Peritonectomy and
intraperitoneal hyperthermic perfusion (IPHP): A strategy that has
confirmed its efficacy in patients with pseudomyxoma peritonei. Ann
Surg Oncol. 11:393–398. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kuijpers AM, Mehta AM, Aalbers AG, van
Driel WJ, Boot H and Verwaal VJ: Treatment of ovarian metastases of
colorectal and appendiceal carcinoma in the era of cytoreductive
surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg
Oncol. 40:937–942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ansaloni L, Agnoletti V, Amadori A, Catena
F, Cavaliere D, Coccolini F, De Iaco P, Di Battista M, Framarini M,
Gazzotti F, et al: Evaluation of extensive cytoreductive surgery
and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients
with advanced epithelial ovarian cancer. Int J Gynecol Cancer.
22:778–785. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pavlov MJ, Kovacevic PA, Ceranic MS,
Stamenkovic AB, Ivanovic AM and Kecmanovic DM: Cytoreductive
surgery and modified heated intraoperative intraperitoneal
chemotherapy (HIPEC) for advanced and recurrent ovarian
cancer-12-year single center experience. Eur J Surg Oncol.
35:1186–1191. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Deraco M, Kusamura S, Virzi S, Puccio F,
Macri A, Famulari C, Solazzo M, Bonomi S, Iusco DR and Baratti D:
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
as upfront therapy for advanced epithelial ovarian cancer:
multi-institutional phase-II trial. Gynecol Oncol. 122:215–220.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tentes AA, Kakolyris S, Kyziridis D and
Karamveri C: Cytoreductive surgery combined with hyperthermic
intraperitoneal intraoperative chemotherapy in the treatment of
advanced epithelial ovarian cancer. J Oncol. 2012:3583412012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Spiliotis J, Vaxevanidou A, Sergouniotis
F, Lambropoulou E, Datsis A and Christopoulou A: The role of
cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
in the management of recurrent advanced ovarian cancer: A
prospective study. J BUON. 16:74–79. 2011.PubMed/NCBI
|
|
27
|
Safra T, Grisaru D, Inbar M, Abu-Abeid S,
Dayan D, Matceyevsky D, Weizman A and Klausner JM: Cytoreduction
surgery with hyperthermic intraperitoneal chemotherapy in recurrent
ovarian cancer improves progression-free survival, especially in
BRCA-positive patients-a case-control study. J Surg Oncol.
110:661–665. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rettenmaier MA, Mendivil AA, Abaid LN,
Brown Iii JV, Wilcox AM and Goldstein BH: Consolidation
hyperthermic intraperitoneal chemotherapy and maintenance
chemotherapy following laparoscopic cytoreductive surgery in the
treatment of ovarian carcinoma. Int J Hyperthermia. 31:8–14. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chiva LM and Gonzalez-Martin A: A critical
appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in
the treatment of advanced and recurrent ovarian cancer. Gynecol
Oncol. 136:130–5. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Munoz-Casares FC, Rufian S, Rubio MJ, Diaz
CJ, Diaz R, Casado A, Arjona A, Muñoz-Villanueva MC and Muntané J:
The role of hyperthermic intraoperative intraperitoneal
chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis
in recurrent ovarian cancer. Clin Transl Oncol. 11:753–759. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Le Brun JF, Campion L, Berton-Rigaud D,
Lorimier G, Marchal F, Ferron G, Oger AS, Dravet F, Jaffre I and
Classe JM: Survival benefit of hyperthermic intraperitoneal
chemotherapy for recurrent ovarian cancer: A multi-institutional
case control study. Ann Surg Oncol. 21:3621–3627. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rettenmaier MA, Mendivil AA, Abaid LN,
Brown JV III, Micha JP, Wilcox AM and Goldstein BH: The feasibility
of administering varying high-dose consolidation hyperthermic
intraperitoneal chemotherapy with carboplatin in the treatment of
ovarian carcinoma. Arch Gynecol Obstet. 291:1381–1386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cascales Campos P, Gil J and Parrilla P:
Morbidity and mortality outcomes of cytoreductive surgery and
hyperthermic intraperitoneal chemotherapy in patients with primary
and recurrent advanced ovarian cancer. Eur J Surg Oncol.
40:970–975. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cascales Campos PA, Gil Martinez J,
Galindo Fernandez PJ, Gil Gomez E, Martinez Frutos IM and Parrilla
Paricio P: Perioperative fast track program in intraoperative
hyperthermic intraperitoneal chemotherapy (HIPEC) after
cytoreductive surgery in advanced ovarian cancer. Eur J Surg Oncol.
37:543–548. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cascales-Campos PA, Gil J, Feliciangeli E,
Gil E, Gonzalez-Gil A, Lopez V, Ruiz-Pardo J, Nieto A, Parrilla JJ
and Parrilla P: The role of hyperthermic intraperitoneal
chemotherapy using paclitaxel in platinum-sensitive recurrent
epithelial ovarian cancer patients with microscopic residual
disease after cytoreduction. Ann Surg Oncol. 22:987–993. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cascales-Campos PA, Gil J, Gil E,
Feliciangeli E, Gonzalez-Gil A, Parrilla JJ and Parrilla P:
Treatment of microscopic disease with hyperthermic intraoperative
intraperitoneal chemotherapy after complete cytoreduction improves
disease-free survival in patients with stage IIIC/IV ovarian
cancer. Ann Surg Oncol. 21:2383–2389. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Coccolini F, Campanati L, Catena F, Ceni
V, Ceresoli M, Jimenez Cruz J, Lotti M, Magnone S, Napoli J,
Rossetti D, et al: Hyperthermic intraperitoneal chemotherapy with
cisplatin and paclitaxel in advanced ovarian cancer: A multicenter
prospective observational study. J Gynecol Oncol. 26:54–61. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Eisenkop SM, Spirtos NM, Friedman RL, Lin
WC, Pisani AL and Perticucci S: Relative influences of tumor volume
before surgery and the cytoreductive outcome on survival for
patients with advanced ovarian cancer: A prospective study. Gynecol
Oncol. 90:390–396. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Coccolini F, Gheza F, Lotti M, Virzi S,
Iusco D, Ghermandi C, Melotti R, Baiocchi G, Giulini SM, Ansaloni L
and Catena F: Peritoneal carcinomatosis. World J Gastroenterol.
19:6979–6994. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Munoz-Casares FC, Rufian S, Rubio MJ,
Lizarraga E, Diaz-Iglesias C, Aranda E, Ciria R, Muntané J, Barrios
P, Torres-Melero J, et al: Treatment of peritoneal carcinomatosis
from ovarian cancer. Present, future directions and proposals. Clin
Transl Oncol. 9:652–662. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fagotti A, Gallotta V, Romano F, Fanfani
F, Rossitto C, Naldini A, Vigliotta M and Scambia G: Peritoneal
carcinosis of ovarian origin. World J Gastrointest Oncol.
2:102–108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Prat J; FIGO Committee on Gynecologic
Oncology, : Staging classification for cancer of the ovary,
fallopian tube, and peritoneum. Int J Gynaecol Obstet. 124:1–5.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sugarbaker PH: Peritonectomy procedures.
Ann Surg. 221:29–42. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Di Giorgio A, Naticchioni E, Biacchi D,
Sibio S, Accarpio F, Rocco M, Tarquini S, Di Seri M, Ciardi A,
Montruccoli D and Sammartino P: Cytoreductive surgery
(peritonectomy procedures) combined with hyperthermic
intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse
peritoneal carcinomatosis from ovarian cancer. Cancer. 113:315–325.
2008. View Article : Google Scholar : PubMed/NCBI
|
